bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. (BIAF) priced its initial public offering on Sep 2, 2022 at $6.12 per share, raising $7.9M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $45.2M. Craft Capital was lead-left underwriter. Carmel, Milazzo & Feil advised the underwriters.

bioAffinity Technologies, Inc. is a Delaware company developing noninvasive diagnostic tests for early-stage cancer and lung disease, and targeted cancer therapeutics. Its platform technologies, which target cancer cells, are researched in laboratories at The University of Texas at San Antonio.

Status

IPO

Ticker

BIAF

Exchange

Nasdaq Capital Market

Priced

Sep 2, 2022

IPO price

$6.12

Raised

$7.9M

Market cap at IPO price

$45.2M

First filed

Apr 25, 2022

Underwriters

Craft Capital

Underwriters' counsel

Carmel, Milazzo & Feil

Sector

Biotech & pharma

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.